Pharmafile Logo
Pharmafocus logo
Advanced Search

suboxone

Showing 5 posts of 5 posts found.

suboxone_sl_tabs

Indivior shares fall by 70% after allegations of fraud

April 10, 2019
Research and Development Virginia, indivior, opioid crisis, opioids, suboxone

Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to …

News
facilities_lg06

Dr Reddy’s just-approved opioid dependence generic blocked over US patent dispute

June 18, 2018
Sales and Marketing Dr Reddy's, FDA, Mylan, US, opioid crisis, opioid dependence, opioids, suboxone

Dr Reddy’s Laboratories has taken two steps forward an one step back after its generic version of Suboxone Film (buprenorphine/naloxone) …

News
shutterstock_235920349

Indivior reaches settlement with Mylan over patent dispute

September 25, 2017
Sales and Marketing Mylan, indivior, patent, pharma, pharmaceutical, suboxone

Indivior has ended a patent dispute with Mylan concerning its heroin addiction therapy Suboxone (buprenorphine and naloxone) sublingual film by …

News
Reckitt image

Reckitt finalises pharmaceutical demerger plans

November 19, 2014
Business Services, Sales and Marketing Reckitt Benckiser Pharmaceuticals, cillit bang, indivior, suboxone

Reckitt Benckiser has confirmed its plans to spin-off its pharmaceutical portfolio from its core consumer products business. Final details of …

News
Reckitt Benckiser image

Reckitt Benckiser may shed pharma unit

October 23, 2013
Sales and Marketing Reckitt Benckiser Pharmaceuticals, rbp, suboxone

Reckitt Benckiser Pharmaceuticals is considering selling its pharma unit within the next year after the recent loss of its biggest …

News

Latest content

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

May 7, 2024

Broken String Biosciences and the Francis Crick Institute collaborate on ALS research

May 7, 2024

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024